Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients

被引：0
作者：
Warit Ruanglertboon
Michael J. Sorich
Andrew Rowland
Ashley M. Hopkins
机构：
[1] Flinders University,Department of Clinical Pharmacology, College of Medicine and Public Health
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Sorafenib; Adverse events; Dose adjustment; Prediction; Survival; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1672 / 1677
页数：5
相关论文
共 66 条
  • [1] Vogel A(2018)Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Ann Oncol 29 238-255
  • [2] Cervantes A(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
  • [3] Chau I(2006)Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 4293-4300
  • [4] Cheng AL(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-181
  • [5] Kang YK(2016)Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study J Hepatol 65 1140-1147
  • [6] Chen Z(2010)Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib Oncologist 15 85-92
  • [7] Abou-Alfa GK(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
  • [8] Schwartz L(2012)Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib Hepatol Res 42 879-886
  • [9] Ricci S(2014)Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma World J Hepatol 6 670-676
  • [10] Trotti A(2013)Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol 31 4067-4075
1234567